Biotech | October 22, 2021
WuXi ATU opens manufacturing facility in Shanghai to enhance its CTDMO services
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The acquisition complements and strengthens Merck’s cardiovascular pipeline
The new devices company will scale up its teams to create a world-class R&D centre for medical devices in India
Subscribe To Our Newsletter & Stay Updated
